Cargando…
Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–20...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443029/ https://www.ncbi.nlm.nih.gov/pubmed/22640166 http://dx.doi.org/10.1186/1471-2407-12-190 |
_version_ | 1782243504810885120 |
---|---|
author | Tjensvoll, Kjersti Oltedal, Satu Heikkilä, Reino Kvaløy, Jan Terje Gilje, Bjørnar Reuben, James M Smaaland, Rune Nordgård, Oddmund |
author_facet | Tjensvoll, Kjersti Oltedal, Satu Heikkilä, Reino Kvaløy, Jan Terje Gilje, Bjørnar Reuben, James M Smaaland, Rune Nordgård, Oddmund |
author_sort | Tjensvoll, Kjersti |
collection | PubMed |
description | BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–2000. Real-time RT-PCR quantification of a DTC multimarker panel consisting of cytokeratin 19, mammaglobin A and TWIST1 mRNA was performed in BM samples obtained from 154 patients three weeks (BM2) and/or six months after surgery (BM3). The results were compared to previously published data from pre-operative BM analyses for the same patients. RESULTS: DTCs were identified in post-operative BM samples (BM2 and/or BM3) from 23 (15%) of the 154 patients investigated. During a median follow-up of 98 months, 10 (44%) of these patients experienced systemic relapse as compared to 16 (12%) of 131 DTC-negative patients. Kaplan-Meier estimates of systemic recurrence-free- and breast-cancer specific survival demonstrated significantly shorter survival for patients with persistent DTCs in BM after surgery (p≤0.001). By multivariate Cox regression analyses, persistent DTCs after surgery was an independent predictor of both systemic recurrence-free- (HR = 5.4, p < 0.001) and breast-cancer specific survival (HR = 5.3, p < 0.001). Furthermore, the prognostic value of DTCs in BM was similar for pre- and post surgery samples. However, patients with DTCs both before and after surgery (BM1 and BM2/3) had a particularly poor prognosis (systemic recurrence-free survival: HR = 7.2, p < 0.0001 and breast-cancer specific survival: HR = 8.0, p < 0.0001). CONCLUSIONS: Detection of persistent DTCs in BM samples obtained after surgery identified non-metastatic breast cancer patients at high risk for systemic relapse, and with reduced breast-cancer specific survival. Furthermore, patients with positive DTC status both before and after surgery had a particularly poor prognosis. |
format | Online Article Text |
id | pubmed-3443029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34430292012-09-15 Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome Tjensvoll, Kjersti Oltedal, Satu Heikkilä, Reino Kvaløy, Jan Terje Gilje, Bjørnar Reuben, James M Smaaland, Rune Nordgård, Oddmund BMC Cancer Research Article BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–2000. Real-time RT-PCR quantification of a DTC multimarker panel consisting of cytokeratin 19, mammaglobin A and TWIST1 mRNA was performed in BM samples obtained from 154 patients three weeks (BM2) and/or six months after surgery (BM3). The results were compared to previously published data from pre-operative BM analyses for the same patients. RESULTS: DTCs were identified in post-operative BM samples (BM2 and/or BM3) from 23 (15%) of the 154 patients investigated. During a median follow-up of 98 months, 10 (44%) of these patients experienced systemic relapse as compared to 16 (12%) of 131 DTC-negative patients. Kaplan-Meier estimates of systemic recurrence-free- and breast-cancer specific survival demonstrated significantly shorter survival for patients with persistent DTCs in BM after surgery (p≤0.001). By multivariate Cox regression analyses, persistent DTCs after surgery was an independent predictor of both systemic recurrence-free- (HR = 5.4, p < 0.001) and breast-cancer specific survival (HR = 5.3, p < 0.001). Furthermore, the prognostic value of DTCs in BM was similar for pre- and post surgery samples. However, patients with DTCs both before and after surgery (BM1 and BM2/3) had a particularly poor prognosis (systemic recurrence-free survival: HR = 7.2, p < 0.0001 and breast-cancer specific survival: HR = 8.0, p < 0.0001). CONCLUSIONS: Detection of persistent DTCs in BM samples obtained after surgery identified non-metastatic breast cancer patients at high risk for systemic relapse, and with reduced breast-cancer specific survival. Furthermore, patients with positive DTC status both before and after surgery had a particularly poor prognosis. BioMed Central 2012-05-28 /pmc/articles/PMC3443029/ /pubmed/22640166 http://dx.doi.org/10.1186/1471-2407-12-190 Text en Copyright ©2012 Tjensvoll et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tjensvoll, Kjersti Oltedal, Satu Heikkilä, Reino Kvaløy, Jan Terje Gilje, Bjørnar Reuben, James M Smaaland, Rune Nordgård, Oddmund Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title | Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title_full | Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title_fullStr | Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title_full_unstemmed | Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title_short | Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
title_sort | persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443029/ https://www.ncbi.nlm.nih.gov/pubmed/22640166 http://dx.doi.org/10.1186/1471-2407-12-190 |
work_keys_str_mv | AT tjensvollkjersti persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT oltedalsatu persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT heikkilareino persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT kvaløyjanterje persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT giljebjørnar persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT reubenjamesm persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT smaalandrune persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome AT nordgardoddmund persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome |